Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181515 | 1.00 | POLB (0.81) | POLBMAOBGFERKDM4ELMNA | |
| SCHEMBL29679184 | 1.00 | POLB (0.81) | POLBMAOBGFERKDM4ELMNA | |
| SCHEMBL31222602 | 1.00 | POLB (0.81) | POLBMAOBGFERKDM4ELMNA | |
| SCHEMBL7743084 | 0.83 | GFER (0.66) | POLBMAOBGFER | |
| SCHEMBL7743081 | 0.83 | GFER (0.66) | POLBMAOBGFER | |
| SCHEMBL1520066 | 0.83 | GFER (0.66) | POLBMAOBGFER | |
| SCHEMBL28554919 | 0.82 | KDM4E (0.66) | POLBMAOBKDM4EMMP9 | |
| SCHEMBL24278570 | 0.82 | POLB (0.78) | POLBMAOBKDM4ELMNAHTT | |
| SCHEMBL6573502 | 0.82 | GFER (0.64) | POLBMAOBGFER | |
| SCHEMBL8443935 | 0.82 | POLB (0.78) | POLBMAOBKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112645897-B | Thiazole derivative and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2022-05-24 | — | — | CN | disclosed |
| CN-112645897-A | Thiazole derivative and preparation method and application thereof | 广东省微生物研究所（广东省微生物分析检测中心） | 2021-04-13 | — | — | CN | disclosed |
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-7851635-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| EP-1399159-A4 | 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| EP-1399159-A1 | 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098420-A1 | 4-SUBSTITUTED-1-(ARYLMETHYLIDENE)THIOSEMICARBAZIDE, 4-SUBSTITUTED-1-(ARYLCARBONYL)THIOSEMICARBAZIDE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | POLB 3345/4885MAOB 2967/4885GFER 3794/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | POLB 773/4885MAOB 3813/4885GFER 4400/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | POLB 3345/4885MAOB 2967/4885GFER 3794/4885 |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | POLB 773/4885MAOB 3813/4885GFER 4400/4885 |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, WDR82, RB1 | POLB 3353/4885MAOB 3115/4885GFER 3619/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | POLB 3345/4885MAOB 2967/4885GFER 3794/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | POLB 773/4885MAOB 3813/4885GFER 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.